Pfizer’s Capsugel Fetches $2.375 Billion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer’s Capsugel Fetches $2.375 Billion


ePT--the Electronic Newsletter of Pharmaceutical Technology

After completing a strategic review of options for its Capsugel business, Pfizer announced on Apr. 04, 2011 that Kohlberg Kravis Roberts & Co L.P  (KKR )agreed to acquire the pharmaceutical and dietary capsule company.

Capsugel generated approximately $750 million in revenue and manufactured more than 180 billion capsules in 2010. According to Guido Driesen, president and general manager of Capsugel, the transaction is “an endorsement of Capsugel’s consistent success to date and its potential for future growth…”

But it also represents Pfizer’s previously announced objectives to streamline its business. Pfizer gained Capsugel in 2000, as part of its $90-billion acquisition of Warner-Lambert, which took over original owner, Parke-Davis, in the 1970s.

KKR co-founders and co-CEOs, Henry Kravis and George Roberts, stated in a Pfizer Apr. 4, 2011 press release that: “Capsugel has an excellent portfolio and outstanding reputation for providing high-quality, innovative drug-delivery solutions.” They also shared Capsugel’s enthusiasm for future potential. KKR has a current private equity portfolio that includes over 60 companies, over $210 billion in annual revenues and more than 900,000 employees.

Pfizer stated that Capsugel will maintain its global headquarters in New Jersey and that any Pfizer staff dedicated to the business would be transferred to Capsugel under the leadership of Guido Driesen.

The sale will enable Pfizer to increase the previously announced $5 billion it plans to spend on the repurchase of its common shares on the open market in 2011. The transaction is expected to close in the third quarter, subject to regulatory and closing requirements.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here